Flash Finance

Advanced Enzyme Technologies LimitedADVENZYMESCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹267.00
MCap ₹2,958 Cr · P/E 17.2
Advanced Enzyme Technologies Limited — Stock analysis & AI research Advanced Enzyme Technologies Limited — Seasonality — best & worst months Advanced Enzyme Technologies Limited — Technical indicators & charts Advanced Enzyme Technologies Limited — Technical setup — score, trend, support & resistance Advanced Enzyme Technologies Limited — Triple Top pattern broken down ↓ Advanced Enzyme Technologies Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Interest Coverage Stocks 📈 Lowest Technical Score📈 Multi-Timeframe Bearish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹190 Cr
Sales · Jun 2026
+2.1% YoY
₹51 Cr
Operating Profit · Jun 2026
-9.7% YoY
26.9%
OPM % · Jun 2026
-11.5% YoY
₹39 Cr
Net Profit · Jun 2026
-4.6% YoY
₹3.31
EPS · Jun 2026
-7.3% YoY

📝 Advanced Enzyme Technologies Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Advanced Enzyme Technologies Limited reported revenue of ₹190 crore for the quarter ended June 2026 (Q1 FY27), up 2.1% from ₹186 crore in the same quarter last year, and down 6.7% sequentially over the March 2026 quarter.

Net profit fell 4.6% year-on-year to ₹39 crore, from ₹40 crore. Earnings per share (EPS) came in at ₹3.31.

Operating profit stood at ₹51 crore — an operating margin (OPM) of 26.9%, compared with 30.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Advanced Enzyme Technologies Limited posted revenue of ₹746 crore, a growth of 17.1% over FY25, with a net profit of ₹174 crore (up 29.6% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹750 crore with a net profit of ₹172 crore.

Valuation snapshot

At the current price of ₹267.00, ADVENZYMES has a market capitalisation of ₹2,958 crore and a trailing P/E of about 17.2.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 17th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 43.56%, foreign institutional investors (FIIs) 26.65%, domestic institutional investors (DIIs) 1.89%, public shareholders 27.90% of Advanced Enzyme Technologies Limited.

Promoter holding rose from 43.24% to 43.56% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,958 Cr
Current Price ?
₹267.0
P/E ?
17.22below ind
Industry P/E ?
37.20
P/B ?
1.81
P/S ?
3.95
P/FCF ?
28.17
Enterprise Value ?
₹2,990 Cr
EV/EBITDA ?
13.37
PEG ?
1.23
Earnings Yield ?
6.1%
Dividend Yield ?
1.95%
Profitability & Returns
Sales (TTM) ?
₹750 Cr
OPM ?
29.8%
Profit after tax (TTM) ?
₹172 Cr
EPS (TTM) ?
₹15.50
ROCE ?
14.0%
ROE ?
10.5%
ROA ?
9.3%
Growth
Sales — latest qtr ?
₹190 Cr
PAT — latest qtr ?
₹39 Cr
YoY qtr sales growth ?
2.1%
YoY qtr profit growth ?
-4.6%
Sales growth (3y) ?
11%
Sales growth (5y) ?
8%
Profit growth (3y) ?
14%
Profit growth (5y) ?
2%
Financial Health
Debt ?
₹32 Cr
Debt to Equity ?
0.02
Interest Coverage ?
71.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
43.56%
Change in promoter holding ?
0.48%
Pledged percentage ?
N/A
Market
Return 3 months ?
-16.7%
Return 6 months ?
-13.1%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 139147158161158155146169167186185172203190 +2.1% -6.7%
Operating Profit 4444515455514255465660496351 -9.7% -19.4%
Other Income 1176149710899108713 +47.1% +80.1%
Interest 11111111111111 -24.1% +1.2%
Depreciation 89999999101010101010 +2.7% -3.1%
Profit Before Tax 4241485940494253435560586054 -2.5% -10.5%
Net Profit 3229354330353339274045434539 -4.6% -14.7%
EPS 2.872.583.083.742.533.052.943.362.373.573.873.803.843.31 -7.3% -13.8%
OPM % 31.8% 29.9% 32.5% 33.4% 35.1% 33.1% 29.0% 32.7% 27.3% 30.4% 32.5% 28.7% 31.1% 26.9% -11.5% -13.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹637 Cr ₹746 Cr ₹750 Cr +17.1%
Operating Profit ₹194 Cr ₹229 Cr ₹224 Cr +17.8%
OPM % 30.53% 30.72% 29.83% +0.6%
NPM % 21.03% 23.28% 22.91% +10.7%
Other Income ₹33 Cr ₹35 Cr ₹39 Cr +5.4%
Depreciation ₹37 Cr ₹40 Cr ₹40 Cr +9.7%
Interest ₹4 Cr ₹3 Cr ₹2 Cr -26.1%
EBIT ₹158 Cr ₹189 Cr ₹183 Cr +19.7%
PBT ₹187 Cr ₹233 Cr ₹231 Cr +24.1%
Tax ₹53 Cr ₹59 Cr ₹59 Cr +10.4%
Net Profit ₹134 Cr ₹174 Cr ₹172 Cr +29.6%
EPS ₹11.72 ₹15.08 ₹14.82 +28.7%
Material Cost ₹162 Cr ₹194 Cr ₹205 Cr +20.0%
Employee Cost ₹142 Cr ₹162 Cr ₹167 Cr +14.7%
Extraordinary Items — ₹-11 Cr ₹-11 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 22222222 +0.0%
Reserves 1,2131,3021,3981,610 +15.2%
Borrowings 34473932 -17.9%
Other Liabilities 142150151175 +15.9%
Total Liabilities 1,4111,5211,6111,839 +14.2%
Fixed Assets 649650679692 +1.9%
CWIP 22412251 +131.8%
Investments 360403480584 +21.7%
Other Assets 380427430511 +18.8%
Total Assets 1,4111,5211,6111,839 +14.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 140141142157 +10.6%
Cash from Investing Activity -286-65-89-74 +16.9%
Cash from Financing Activity -26-59-73-70 +4.1%
Net Cash Flow -17117-2012 +160.0%
Free Cash Flow 10294108105 -2.8%
CFO/OP 112%93%103%97% -5.8%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 68586671 +7.6%
Inventory Days 343375378335 -11.4%
Days Payable 67404176 +85.4%
Cash Conversion Cycle 344393403331 -17.9%
Working Capital Days 109102112402 +258.9%
ROCE % 12%15%13%14% +7.7%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 43.08%43.08%43.04%43.26%43.24%43.56% +0.7%
FIIs 23.45%25.41%25.85%25.50%26.71%26.65% -0.2%
DIIs 8.45%6.41%5.51%5.41%4.78%1.89% -60.5%
Public 25.00%25.09%25.62%25.85%25.27%27.90% +10.4%
No. of Shareholders 67,58969,63768,05166,19363,59967,468 +6.1%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Advanced Enzyme Technologies Limited's revenue in Q1 FY27?
Advanced Enzyme Technologies Limited reported revenue of ₹190 crore for the quarter ended June 2026 (Q1 FY27), up 2.1% from ₹186 crore in the same quarter last year, and down 6.7% sequentially over the March 2026 quarter.
What was Advanced Enzyme Technologies Limited's net profit in Q1 FY27?
Net profit fell 4.6% year-on-year to ₹39 crore, from ₹40 crore. Earnings per share (EPS) came in at ₹3.31.
What is ADVENZYMES's market capitalisation and P/E ratio?
At the current price of ₹267.00, ADVENZYMES has a market capitalisation of ₹2,958 crore and a trailing P/E of about 17.2.
Who owns Advanced Enzyme Technologies Limited? (shareholding pattern)
As of Sep 2026, promoters held 43.56%, foreign institutional investors (FIIs) 26.65%, domestic institutional investors (DIIs) 1.89%, public shareholders 27.90% of Advanced Enzyme Technologies Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI